IP Library › Granted Patent US 10,207,022
Granted Patent B2
US 10,207,022 · App. 13/393,006 · Granted Feb 19, 2019

Chitosan tissue dressing

Inventors: Rivelino Montenegro (Mainz, DE); Thomas Freier (Mainz, DE)
Assignee: MEDODERM GMBH
A61L26/0023A61L15/28A61L26/0066A61L2300/232A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,207,022
App. No.
13/393,006
Granted
Feb 19, 2019
Kind
B2
Abstract

A tissue dressing material for being applied in contact with a tissue of a patient. The tissue dressing material's main component is deacetylated native chitosan. Moreover, a liquid tissue dressing material for being applied in contact with a tissue of a patient, the tissue dressing material being an aqueous mixture. The main component of the constituent(s) of the mixture other than water is deacetylated native chitosan.

Claims (28)

1. A tissue dressing material for being applied in contact with a tissue of a patient comprising at least 50% by weight native chitosan having a degree of acetylation below 2.5%, wherein the water uptake capacity of a solid phase of the tissue dressing material is less than 100% by weight.

2. The tissue dressing material according to claim 1 , wherein the tissue dressing material is present in the form of a solid or gel-like film.

3. The tissue dressing material according to claim 1 , wherein at least 70% by weight of the tissue dressing material is deacetylated native chitosan.

4. A liquid tissue dressing material for being applied in contact with a tissue of a patient, the tissue dressing material being an aqueous mixture comprising at least 50% by weight of the combination of all constituents other than water native chitosan having a degree of acetylation below 2.5%, wherein the tissue dressing material has a pH above 4.5.

5. The tissue dressing material according to claim 4 , wherein at least 70% by weight of the constituent(s) of the mixture other than water is deacetylated native chitosan.

6. The tissue dressing material according to claim 1 or 4 , wherein

the native chitosan's degree of acetylation is below or equal to 2%.

7. The tissue dressing material according to claim 1 or 4 , wherein

the native chitosan is at least partly present as a chitosan salt.

8. The tissue dressing material according to claim 1 or 4 , wherein

the tissue dressing material comprises at least one pharmaceutically active compound.

9. The tissue dressing material according to claim 1 or 4 , wherein

the tissue dressing material has a pH below 6.3.

10. The tissue dressing material according to claim 1 or 4 , wherein

the tissue dressing material is transparent.

11. A tissue dressing, comprising:

a first layer, which layer is formed of the tissue dressing material according to claim 1 or 4 , and

another layer formed of another material.

12. The tissue dressing of claim 11 , wherein

the other layer acts as a support.

13. The tissue dressing of claim 11 , wherein

the other layer acts as an at least partial moisture barrier.

14. A method of treating a tissue of a patient, comprising a step of applying a tissue dressing material in contact with the tissue of the patient,

the tissue dressing material comprising at least 50% by weight native chitosan having a degree of acetylation below 2.5%,

wherein the water uptake capacity of a solid phase of the tissue dressing material is less than 100% by weight.

15. A method of treating a tissue of a patient, comprising a step of

applying a liquid tissue dressing material in contact with the tissue of the patient, the tissue dressing material being an aqueous mixture, the tissue dressing material comprising at least 50% by weight of the combination of all constituents other than water, native chitosan, having a degree of acetylation below 2.5%, wherein the tissue dressing material has a pH above 4.5.

16. The method of claim 14 or 15 wherein the method of treating is locally confined antibacterial treatment of the patient's tissue.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2018
From: MEDOVENT GMBH
To: MEDODERM GMBH
Reel/Frame 047439/0037 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2012
From: MONTENEGRO, RIVELINO; FREIER, THOMAS
To: MEDOVENT GMBH
Reel/Frame 028010/0530 →
Continuity (1)
Related Publication 20120215149A1 · Aug 23, 2012
Cited By (2)
US 12,232,944 US 12,569,590